<exch:exchange-document country="WO" doc-number="2023012807" kind="A1" doc-id="587406416" date-publ="20230209" family-id="83004620" is-representative="YES" date-of-last-exchange="20230219" date-added-docdb="20230210" originating-office="EP"><exch:bibliographic-data><exch:publication-reference data-format="docdb"><document-id lang="en"><country>WO</country><doc-number>2023012807</doc-number><kind>A1</kind><date>20230209</date></document-id></exch:publication-reference><exch:publication-reference data-format="epodoc"><document-id lang="en"><doc-number>WO2023012807</doc-number></document-id></exch:publication-reference><exch:publication-reference data-format="original"><document-id><doc-number>2023/012807</doc-number></document-id></exch:publication-reference><exch:extended-kind-code>x</exch:extended-kind-code><exch:classifications-ipcr><classification-ipcr sequence="1"><text>C07K  16/28        20060101AFI20230209BHEP        </text></classification-ipcr><classification-ipcr sequence="2"><text>C07K  16/30        20060101ALI20230209BHEP        </text></classification-ipcr><classification-ipcr sequence="3"><text>C07K  16/40        20060101ALI20230209BHEP        </text></classification-ipcr><classification-ipcr sequence="4"><text>C07K  16/46        20060101ALI20230209BHEP        </text></classification-ipcr></exch:classifications-ipcr><exch:patent-classifications><patent-classification sequence="1"><classification-scheme office="EP" scheme="CPCI"><date>20130101</date></classification-scheme><classification-symbol>C07K  16/464       </classification-symbol><symbol-position>F</symbol-position><classification-value>I</classification-value><classification-status>B</classification-status><classification-data-source>H</classification-data-source><generating-office>EP</generating-office><action-date><date>20221018</date></action-date></patent-classification><patent-classification sequence="2"><classification-scheme office="EP" scheme="CPCI"><date>20130101</date></classification-scheme><classification-symbol>C07K  16/2863      </classification-symbol><symbol-position>L</symbol-position><classification-value>I</classification-value><classification-status>B</classification-status><classification-data-source>H</classification-data-source><generating-office>EP</generating-office><action-date><date>20221018</date></action-date></patent-classification><patent-classification sequence="3"><classification-scheme office="EP" scheme="CPCI"><date>20130101</date></classification-scheme><classification-symbol>C07K  16/3069      </classification-symbol><symbol-position>L</symbol-position><classification-value>I</classification-value><classification-status>B</classification-status><classification-data-source>H</classification-data-source><generating-office>EP</generating-office><action-date><date>20221018</date></action-date></patent-classification><patent-classification sequence="4"><classification-scheme office="EP" scheme="CPCI"><date>20130101</date></classification-scheme><classification-symbol>C07K  16/40        </classification-symbol><symbol-position>L</symbol-position><classification-value>I</classification-value><classification-status>B</classification-status><classification-data-source>H</classification-data-source><generating-office>EP</generating-office><action-date><date>20221018</date></action-date></patent-classification><patent-classification sequence="5"><classification-scheme office="EP" scheme="CPCI"><date>20130101</date></classification-scheme><classification-symbol>C07K  16/462       </classification-symbol><symbol-position>L</symbol-position><classification-value>I</classification-value><classification-status>B</classification-status><classification-data-source>H</classification-data-source><generating-office>EP</generating-office><action-date><date>20221018</date></action-date></patent-classification><patent-classification sequence="6"><classification-scheme office="EP" scheme="CPCI"><date>20130101</date></classification-scheme><classification-symbol>C07K2317/24        </classification-symbol><symbol-position>L</symbol-position><classification-value>A</classification-value><classification-status>B</classification-status><classification-data-source>H</classification-data-source><generating-office>EP</generating-office><action-date><date>20221018</date></action-date></patent-classification><patent-classification sequence="7"><classification-scheme office="EP" scheme="CPCI"><date>20130101</date></classification-scheme><classification-symbol>C07K2317/55        </classification-symbol><symbol-position>L</symbol-position><classification-value>A</classification-value><classification-status>B</classification-status><classification-data-source>H</classification-data-source><generating-office>EP</generating-office><action-date><date>20221018</date></action-date></patent-classification><patent-classification sequence="8"><classification-scheme office="EP" scheme="CPCI"><date>20130101</date></classification-scheme><classification-symbol>C07K2317/92        </classification-symbol><symbol-position>L</symbol-position><classification-value>A</classification-value><classification-status>B</classification-status><classification-data-source>H</classification-data-source><generating-office>EP</generating-office><action-date><date>20221018</date></action-date></patent-classification><patent-classification sequence="9"><classification-scheme office="EP" scheme="CPCI"><date>20130101</date></classification-scheme><classification-symbol>C07K2317/94        </classification-symbol><symbol-position>L</symbol-position><classification-value>A</classification-value><classification-status>B</classification-status><classification-data-source>H</classification-data-source><generating-office>EP</generating-office><action-date><date>20221018</date></action-date></patent-classification></exch:patent-classifications><exch:application-reference is-representative="YES" doc-id="577915875" data-format="docdb"><document-id><country>IL</country><doc-number>2022050854</doc-number><kind>W</kind><date>20220805</date></document-id></exch:application-reference><exch:application-reference data-format="epodoc"><document-id><doc-number>WO2022IL50854</doc-number></document-id></exch:application-reference><exch:application-reference data-format="original"><document-id><doc-number>IL2022/050854</doc-number></document-id></exch:application-reference><exch:language-of-filing>en</exch:language-of-filing><exch:priority-claims><exch:priority-claim sequence="1" data-format="docdb"><document-id><country>US</country><doc-number>202163230089</doc-number><kind>P</kind><date>20210806</date></document-id><exch:priority-active-indicator>Y</exch:priority-active-indicator></exch:priority-claim><exch:priority-claim sequence="1" data-format="epodoc"><document-id><doc-number>US202163230089P</doc-number></document-id></exch:priority-claim><exch:priority-claim sequence="1" data-format="original"><document-id><doc-number>63/230,089</doc-number></document-id></exch:priority-claim></exch:priority-claims><exch:parties><exch:applicants><exch:applicant sequence="1" data-format="docdb"><exch:applicant-name><name>YEDA RES &amp; DEV                                                                                      </name></exch:applicant-name><residence><country>IL</country></residence></exch:applicant><exch:applicant sequence="1" data-format="docdba"><exch:applicant-name><name>YEDA RESEARCH AND DEVELOPMENT CO. LTD.</name></exch:applicant-name></exch:applicant></exch:applicants><exch:inventors><exch:inventor sequence="1" data-format="docdb"><exch:inventor-name><name>FLEISHMAN SAREL</name></exch:inventor-name><residence><country>IL</country></residence></exch:inventor><exch:inventor sequence="2" data-format="docdb"><exch:inventor-name><name>TENNENHOUSE ARIEL</name></exch:inventor-name><residence><country>IL</country></residence></exch:inventor><exch:inventor sequence="1" data-format="docdba"><exch:inventor-name><name>FLEISHMAN, Sarel</name></exch:inventor-name></exch:inventor><exch:inventor sequence="2" data-format="docdba"><exch:inventor-name><name>TENNENHOUSE, Ariel</name></exch:inventor-name></exch:inventor></exch:inventors></exch:parties><exch:designation-of-states><exch:designation-pct><exch:regional><region><country>AP</country></region><country>BW</country><country>GH</country><country>GM</country><country>KE</country><country>LR</country><country>LS</country><country>MW</country><country>MZ</country><country>NA</country><country>RW</country><country>SD</country><country>SL</country><country>SZ</country><country>TZ</country><country>UG</country><country>ZM</country><country>ZW</country></exch:regional><exch:regional><region><country>EA</country></region><country>AM</country><country>AZ</country><country>BY</country><country>KG</country><country>KZ</country><country>RU</country><country>TJ</country><country>TM</country></exch:regional><exch:regional><region><country>EP</country></region><country>AL</country><country>AT</country><country>BE</country><country>BG</country><country>CH</country><country>CY</country><country>CZ</country><country>DE</country><country>DK</country><country>EE</country><country>ES</country><country>FI</country><country>FR</country><country>GB</country><country>GR</country><country>HR</country><country>HU</country><country>IE</country><country>IS</country><country>IT</country><country>LT</country><country>LU</country><country>LV</country><country>MC</country><country>MK</country><country>MT</country><country>NL</country><country>NO</country><country>PL</country><country>PT</country><country>RO</country><country>RS</country><country>SE</country><country>SI</country><country>SK</country><country>SM</country><country>TR</country></exch:regional><exch:regional><region><country>OA</country></region><country>BF</country><country>BJ</country><country>CF</country><country>CG</country><country>CI</country><country>CM</country><country>GA</country><country>GN</country><country>GQ</country><country>GW</country><country>KM</country><country>ML</country><country>MR</country><country>NE</country><country>SN</country><country>TD</country><country>TG</country><country>ST</country></exch:regional><exch:national><country>AE</country><country>AG</country><country>AL</country><country>AM</country><country>AO</country><country>AT</country><country>AU</country><country>AZ</country><country>BA</country><country>BB</country><country>BG</country><country>BH</country><country>BN</country><country>BR</country><country>BW</country><country>BY</country><country>BZ</country><country>CA</country><country>CH</country><country>CL</country><country>CN</country><country>CO</country><country>CR</country><country>CU</country><country>CV</country><country>CZ</country><country>DE</country><country>DJ</country><country>DK</country><country>DM</country><country>DO</country><country>DZ</country><country>EC</country><country>EE</country><country>EG</country><country>ES</country><country>FI</country><country>GB</country><country>GD</country><country>GE</country><country>GH</country><country>GM</country><country>GT</country><country>HN</country><country>HR</country><country>HU</country><country>ID</country><country>IL</country><country>IN</country><country>IQ</country><country>IR</country><country>IS</country><country>IT</country><country>JM</country><country>JO</country><country>JP</country><country>KE</country><country>KG</country><country>KH</country><country>KN</country><country>KP</country><country>KR</country><country>KW</country><country>KZ</country><country>LA</country><country>LC</country><country>LK</country><country>LR</country><country>LS</country><country>LU</country><country>LY</country><country>MA</country><country>MD</country><country>ME</country><country>MG</country><country>MK</country><country>MN</country><country>MW</country><country>MX</country><country>MY</country><country>MZ</country><country>NA</country><country>NG</country><country>NI</country><country>NO</country><country>NZ</country><country>OM</country><country>PA</country><country>PE</country><country>PG</country><country>PH</country><country>PL</country><country>PT</country><country>QA</country><country>RO</country><country>RS</country><country>RU</country><country>RW</country><country>SA</country><country>SC</country><country>SD</country><country>SE</country><country>SG</country><country>SK</country><country>SL</country><country>ST</country><country>SV</country><country>SY</country><country>TH</country><country>TJ</country><country>TM</country><country>TN</country><country>TR</country><country>TT</country><country>TZ</country><country>UA</country><country>UG</country><country>US</country><country>UZ</country><country>VC</country><country>VN</country><country>WS</country><country>ZA</country><country>ZM</country><country>ZW</country></exch:national></exch:designation-pct></exch:designation-of-states><exch:invention-title lang="en" data-format="docdba">METHOD FOR HUMANIZING ANTIBODIES</exch:invention-title><exch:invention-title lang="fr" data-format="docdba">PROCÉDÉ D'HUMANISATION D'ANTICORPS</exch:invention-title><exch:dates-of-public-availability><exch:examined-printed-without-grant><document-id><date>20230209</date></document-id></exch:examined-printed-without-grant></exch:dates-of-public-availability><exch:references-cited><exch:citation cited-phase="ISR" cited-date="20221031" srep-office="EP" sequence="1"><nplcit num="1" npl-type="w" extracted-xp="055973120"><text>CHIN MARK ET AL: "Humanization of antibodies using a machine learning approach on large-scale repertoire data", BIORXIV, 11 January 2021 (2021-01-11), XP055973120, Retrieved from the Internet &lt;URL:https://www.biorxiv.org/content/10.1101/2021.01.08.425894v2.full.pdf&gt; [retrieved on 20221020], DOI: 10.1101/2021.01.08.425894</text><online><author><name>Chin Mark ET AL</name></author><online-title>Humanization of antibodies using a machine learning approach on large-scale repertoire data</online-title><serial><sertitle>bioRxiv</sertitle><doi>10.1101/2021.01.08.425894</doi></serial><pubdate><sdate>20210111</sdate></pubdate><avail>https://www.biorxiv.org/content/10.1101/2021.01.08.425894v2.full.pdf</avail><srchdate><date>20221020</date></srchdate></online></nplcit><rel-passage><passage><pp>W</pp>e.g. abstract; page 2, section "Classification performance of our Random Forest (RF) models on OAS sequences."; section "Relationship of RF model scores with immunogenicity." starting on page 2; page 5, left-hand column, paragraph 1; page 5, right-hand column, last paragraph</passage><category>X</category><rel-claims>1-4,7-9</rel-claims><category>Y</category><rel-claims>5,6</rel-claims></rel-passage><category>XY</category></exch:citation><exch:citation cited-phase="ISR" cited-date="20221031" srep-office="EP" sequence="2"><nplcit num="2" npl-type="s" extracted-xp="055377037"><text>THOMAS TILLER ET AL: "A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical properties", MABS, vol. 5, no. 3, 1 May 2013 (2013-05-01), US, pages 445 - 470, XP055377037, ISSN: 1942-0862, DOI: 10.4161/mabs.24218</text><article><author><name>THOMAS TILLER ET AL</name></author><atl>A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical properties</atl><serial><sertitle>MABS</sertitle><imprint><address><text>US</text></address><name></name></imprint><pubdate><sdate>20130501</sdate></pubdate><vid>5</vid><ino>3</ino><doi>10.4161/mabs.24218</doi><issn>1942-0862</issn></serial><location><pp><ppf>445</ppf><ppl>470</ppl></pp></location></article></nplcit><rel-passage><passage><pp>W</pp>e.g. page 446, left-hand column, last paragraph</passage><category>Y</category><rel-claims>5,6</rel-claims></rel-passage><category>Y</category></exch:citation><exch:citation cited-phase="ISR" cited-date="20221031" srep-office="EP" sequence="3"><nplcit num="3" npl-type="s" extracted-xp="055416058"><text>JINWOO LEEM ET AL: "ABodyBuilder: Automated antibody structure prediction with data&ndash;driven accuracy estimation", MABS, vol. 8, no. 7, 8 July 2016 (2016-07-08), US, pages 1259 - 1268, XP055416058, ISSN: 1942-0862, DOI: 10.1080/19420862.2016.1205773</text><article><author><name>JINWOO LEEM ET AL</name></author><atl>ABodyBuilder: Automated antibody structure prediction with data&ndash;driven accuracy estimation</atl><serial><sertitle>MABS</sertitle><imprint><address><text>US</text></address><name></name></imprint><pubdate><sdate>20160708</sdate></pubdate><vid>8</vid><ino>7</ino><doi>10.1080/19420862.2016.1205773</doi><issn>1942-0862</issn></serial><location><pp><ppf>1259</ppf><ppl>1268</ppl></pp></location></article></nplcit><rel-passage><passage><pp>W</pp>determine the order of CDR loop modeling by calculating the RMSD between CDR loops was known in the e.g. page 1265, section "Calculation of model accuracy"</passage><category>Y</category><rel-claims>5,6</rel-claims></rel-passage><category>Y</category></exch:citation><exch:citation cited-phase="ISR" cited-date="20221031" srep-office="EP" sequence="4"><nplcit num="4" npl-type="w" extracted-xp="055920361"><text>RUFFOLO JEFFREY A ET AL: "Antibody structure prediction using interpretable deep learning", 11 February 2022 (2022-02-11), XP055920361, Retrieved from the Internet &lt;URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848015/pdf/main.pdf&gt; [retrieved on 20220511]</text><online><author><name>Ruffolo Jeffrey A ET AL</name></author><online-title>Antibody structure prediction using interpretable deep learning</online-title><pubdate><sdate>20220211</sdate></pubdate><avail>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848015/pdf/main.pdf</avail><srchdate><date>20220511</date></srchdate></online></nplcit><rel-passage><passage><pp>W</pp>e.g. page 3, right-hand column, paragraph 2</passage><category>IP</category><rel-claims>1-9</rel-claims></rel-passage><category>IP</category></exch:citation><exch:citation cited-phase="ISR" cited-date="20221031" srep-office="EP" sequence="5"><patcit num="1" dnum="US2020223945A1" dnum-type="publication number"><document-id doc-id="534564725"><country>US</country><doc-number>2020223945</doc-number><kind>A1</kind><name>AUER JOHANNES [DE], et al</name><date>20200716</date></document-id></patcit><rel-passage><passage><pp>W</pp>e.g. paragraphs 121-134</passage><category>X</category><rel-claims>1-4,7-9</rel-claims><category>Y</category><rel-claims>5,6</rel-claims></rel-passage><category>XY</category></exch:citation><exch:citation cited-phase="APP" sequence="1"><patcit num="1" dnum="US8343489B2" dnum-type="publication number"><document-id doc-id="379524255"><country>US</country><doc-number>8343489</doc-number><kind>B2</kind><name>WEAVER DAVID T [US], et al</name><date>20130101</date></document-id></patcit></exch:citation><exch:citation cited-phase="APP" sequence="2"><patcit num="2" dnum="WO2019025299A1" dnum-type="publication number"><document-id doc-id="507242069"><country>WO</country><doc-number>2019025299</doc-number><kind>A1</kind><name>HOFFMANN LA ROCHE [CH], et al</name><date>20190207</date></document-id></patcit></exch:citation><exch:citation cited-phase="APP" sequence="3"><nplcit num="1" npl-type="s"><text>KASHMIRI, S. V. S.DE PASCALIS, R.GONZALES, N. R.SCHLOM, J.: "SDR Grafting - A New Approach to Antibody Humanization", METHODS, vol. 36, no. 1, 2005, pages 25 - 34</text><article><author><name>KASHMIRI, S. V. S.DE PASCALIS, R.GONZALES, N. R.SCHLOM, J.</name></author><atl>SDR Grafting - A New Approach to Antibody Humanization</atl><serial><sertitle>Methods</sertitle><pubdate><sdate>20050000</sdate></pubdate><vid>36</vid><ino>1</ino></serial><location><pp><ppf>25</ppf><ppl>34</ppl></pp></location></article></nplcit></exch:citation><exch:citation cited-phase="APP" sequence="4"><nplcit num="2" npl-type="s" extracted-xp="009096781"><text>LEFRANC, M. P.: "Nomenclature of the Human Immunoglobulin Kappa (IGK) Genes", EXP. CLIN. IMMUNOGENET., vol. 18, no. 3, 2001, pages 161 - 174, XP009096781, DOI: 10.1159/000049195</text><article><author><name>LEFRANC, M. P.</name></author><atl>Nomenclature of the Human Immunoglobulin Kappa (IGK) Genes</atl><serial><sertitle>Exp. Clin. Immunogenet.</sertitle><pubdate><sdate>20010000</sdate></pubdate><vid>18</vid><ino>3</ino><doi>10.1159/000049195</doi></serial><location><pp><ppf>161</ppf><ppl>174</ppl></pp></location></article></nplcit></exch:citation><exch:citation cited-phase="APP" sequence="5"><nplcit num="3" npl-type="s" extracted-xp="002242391"><text>MACCALLUM, R. M.MARTIN, A. C.THORNTON, J. M.: "Antibody-Antigen Interactions: Contact Analysis and Binding Site Topography", J. MOL. BIOL., vol. 262, no. 5, 1996, pages 732 - 745, XP002242391, DOI: 10.1006/jmbi.1996.0548</text><article><author><name>MACCALLUM, R. M.MARTIN, A. C.THORNTON, J. M.</name></author><atl>Antibody-Antigen Interactions: Contact Analysis and Binding Site Topography</atl><serial><sertitle>J. Mol. Biol.</sertitle><pubdate><sdate>19960000</sdate></pubdate><vid>262</vid><ino>5</ino><doi>10.1006/jmbi.1996.0548</doi></serial><location><pp><ppf>732</ppf><ppl>745</ppl></pp></location></article></nplcit></exch:citation><exch:citation cited-phase="APP" sequence="6"><nplcit num="4" npl-type="s"><text>DONDELINGER, M.FILEE, P.SAUVAGE, E.QUINTING, B.MUYLDERMANS, S.GALLENI, M.VANDEVENNE, M. S.: "Understanding the Significance and Implications of Antibody Numbering and Antigen-Binding Surface/Residue Definition", FRONT. IMMUNOL., vol. 9, 2018, pages 2278</text><article><author><name>DONDELINGER, M.FILEE, P.SAUVAGE, E.QUINTING, B.MUYLDERMANS, S.GALLENI, M.VANDEVENNE, M. S.</name></author><atl>Understanding the Significance and Implications of Antibody Numbering and Antigen-Binding Surface/Residue Definition</atl><serial><sertitle>Front. Immunol.</sertitle><pubdate><sdate>20180000</sdate></pubdate><vid>9</vid></serial><location><pp><ppf>2278</ppf></pp></location></article></nplcit></exch:citation><exch:citation cited-phase="APP" sequence="7"><nplcit num="5" npl-type="s" extracted-xp="055621108"><text>LEAVER-FAY, A.TYKA, M.LEWIS, S. M.LANGE, O. F.THOMPSON, J.JACAK, R.KAUFMAN, K.RENFREW, P. D.SMITH, C. A.SHEFFLER, W.: "ROSETTA3: An Object-Oriented Software Suite for the Simulation and Design of Macromolecules", METHODS ENZYMOL., vol. 487, 2011, pages 545 - 574, XP055621108, DOI: 10.1016/B978-0-12-381270-4.00019-6</text><article><author><name>LEAVER-FAY, A.TYKA, M.LEWIS, S. M.LANGE, O. F.THOMPSON, J.JACAK, R.KAUFMAN, K.RENFREW, P. D.SMITH, C. A.SHEFFLER, W.</name></author><atl>ROSETTA3: An Object-Oriented Software Suite for the Simulation and Design of Macromolecules</atl><serial><sertitle>Methods Enzymol.</sertitle><pubdate><sdate>20110000</sdate></pubdate><vid>487</vid><doi>10.1016/B978-0-12-381270-4.00019-6</doi></serial><location><pp><ppf>545</ppf><ppl>574</ppl></pp></location></article></nplcit></exch:citation><exch:citation cited-phase="APP" sequence="8"><nplcit num="6" npl-type="s" extracted-xp="055565500"><text>STEIN, AHOULIHAN, K.DIMAIO, F.BRADLEY, P.KORTEMME, T.BAKER, D.SNOEYINK, J.KUHLMAN, B: "A Combined Covalent-Electrostatic Model of Hydrogen Bonding Improves Structure Prediction with Rosetta", J. CHEM. THEORY COMPUT., vol. 11, no. 2, 2015, pages 609 - 622, XP055565500, DOI: 10.1021/ct500864r</text><article><author><name>STEIN, AHOULIHAN, K.DIMAIO, F.BRADLEY, P.KORTEMME, T.BAKER, D.SNOEYINK, J.KUHLMAN, B</name></author><atl>A Combined Covalent-Electrostatic Model of Hydrogen Bonding Improves Structure Prediction with Rosetta</atl><serial><sertitle>J. Chem. Theory Comput.</sertitle><pubdate><sdate>20150000</sdate></pubdate><vid>11</vid><ino>2</ino><doi>10.1021/ct500864r</doi></serial><location><pp><ppf>609</ppf><ppl>622</ppl></pp></location></article></nplcit></exch:citation><exch:citation cited-phase="APP" sequence="9"><nplcit num="7" npl-type="s"><text>GROSSMAN, I.ALON, A.ILANI, T.FASS, D: "An Inhibitory Antibody Blocks the First Step in the Dithiolldisulfide Relay Mechanism of the Enzyme QSOXI", J. MOL. BIOL., vol. 425, no. 22, 2013, pages 4366 - 4378</text><article><author><name>GROSSMAN, I.ALON, A.ILANI, T.FASS, D</name></author><atl>An Inhibitory Antibody Blocks the First Step in the Dithiolldisulfide Relay Mechanism of the Enzyme QSOXI</atl><serial><sertitle>J. Mol. Biol.</sertitle><pubdate><sdate>20130000</sdate></pubdate><vid>425</vid><ino>22</ino></serial><location><pp><ppf>4366</ppf><ppl>4378</ppl></pp></location></article></nplcit></exch:citation><exch:citation cited-phase="APP" sequence="10"><nplcit num="8" npl-type="s"><text>WARSZAWSKI, S.BORENSTEIN KATZ, ALIPSH, R.KHMELNITSKY, L.BEN NISSAN, G.JAVITT, G.DYM, O.UNGER, T.KNOP, O.ALBECK, S.: "Optimizing Antibody Affinity and Stability by the Automated Design of the Variable Light-Heavy Chain Interfaces", PLOS COMPUT. BIOL., vol. 16, no. 10, 2020, pages e1008382</text><article><author><name>WARSZAWSKI, S.BORENSTEIN KATZ, ALIPSH, R.KHMELNITSKY, L.BEN NISSAN, G.JAVITT, G.DYM, O.UNGER, T.KNOP, O.ALBECK, S.</name></author><atl>Optimizing Antibody Affinity and Stability by the Automated Design of the Variable Light-Heavy Chain Interfaces</atl><serial><sertitle>PLoS Comput. Biol.</sertitle><pubdate><sdate>20200000</sdate></pubdate><vid>16</vid><ino>10</ino></serial><location><pp><ppf>e1008382</ppf></pp></location></article></nplcit></exch:citation><exch:citation cited-phase="APP" sequence="11"><nplcit num="9" npl-type="s"><text>ALMAGRO, J. C.TEPLYAKOV, A.LUO, J.SWEET, R. W.KODANGATTIL, S.HERNANDEZ-GUZMAN, F.GILLILAND, G. L.: "Second Antibody Modeling Assessment (AMA-II). Proteins", STRUCT. FUNCT. BIOINF., vol. 82, no. 8, 2014, pages 1553 - 1562</text><article><author><name>ALMAGRO, J. C.TEPLYAKOV, A.LUO, J.SWEET, R. W.KODANGATTIL, S.HERNANDEZ-GUZMAN, F.GILLILAND, G. L.</name></author><atl>Second Antibody Modeling Assessment (AMA-II). Proteins</atl><serial><sertitle>Struct. Funct. Bioinf.</sertitle><pubdate><sdate>20140000</sdate></pubdate><vid>82</vid><ino>8</ino></serial><location><pp><ppf>1553</ppf><ppl>1562</ppl></pp></location></article></nplcit></exch:citation><exch:citation cited-phase="APP" sequence="12"><nplcit num="10" npl-type="s"><text>LAPIDOTH, G.PARKER, J.PRILUSKY, J.FLEISHMAN, S. J.: "AbPredict 2: A Server for Accurate and Unstrained Structure Prediction of Antibody Variable Domains", BIOINFORMATICS, vol. 35, no. 9, 2019, pages 1591 - 1593</text><article><author><name>LAPIDOTH, G.PARKER, J.PRILUSKY, J.FLEISHMAN, S. J.</name></author><atl>AbPredict 2: A Server for Accurate and Unstrained Structure Prediction of Antibody Variable Domains</atl><serial><sertitle>Bioinformatics</sertitle><pubdate><sdate>20190000</sdate></pubdate><vid>35</vid><ino>9</ino></serial><location><pp><ppf>1591</ppf><ppl>1593</ppl></pp></location></article></nplcit></exch:citation><exch:citation cited-phase="APP" sequence="13"><nplcit num="11" npl-type="s" extracted-xp="002402423"><text>DE PASCALIS, R.IWAHASHI, M.TAMURA, M.PADLAN, E. A.GONZALES, N. R.SANTOS, A. D.GIULIANO, M.SCHUCK, P.SCHLOM, J.KASHMIRI, S. V. S.: "Grafting of ''Abbreviated'' Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody", THE JOURNAL OF IMMUNOLOGY, vol. 169, no. 6, 2002, pages 3076 - 3084, XP002402423</text><article><author><name>DE PASCALIS, R.IWAHASHI, M.TAMURA, M.PADLAN, E. A.GONZALES, N. R.SANTOS, A. D.GIULIANO, M.SCHUCK, P.SCHLOM, J.KASHMIRI, S. V. S.</name></author><atl>Grafting of ''Abbreviated'' Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody</atl><serial><sertitle>The Journal of Immunology</sertitle><pubdate><sdate>20020000</sdate></pubdate><vid>169</vid><ino>6</ino></serial><location><pp><ppf>3076</ppf><ppl>3084</ppl></pp></location></article></nplcit></exch:citation><exch:citation cited-phase="APP" sequence="14"><nplcit num="12" npl-type="s" extracted-xp="002520702"><text>CHAO, G.LAU, W. L.HACKEL, B. J.SAZINSKY, S. L.LIPPOW, S. M.WITTRUP, K. D.: "Isolating and Engineering Human Antibodies Using Yeast Surface Display", NAT. PROTOC., vol. 1, no. 2, 2006, pages 755 - 768, XP002520702, DOI: 10.1038/NPROT.2006.94</text><article><author><name>CHAO, G.LAU, W. L.HACKEL, B. J.SAZINSKY, S. L.LIPPOW, S. M.WITTRUP, K. D.</name></author><atl>Isolating and Engineering Human Antibodies Using Yeast Surface Display</atl><serial><sertitle>Nat. Protoc.</sertitle><pubdate><sdate>20060000</sdate></pubdate><vid>1</vid><ino>2</ino><doi>10.1038/NPROT.2006.94</doi></serial><location><pp><ppf>755</ppf><ppl>768</ppl></pp></location></article></nplcit></exch:citation><exch:citation cited-phase="APP" sequence="15"><nplcit num="13" npl-type="b"><text>CHRISTODOULOS A. FLOUDASPANOS M. PARDALOS: "Encyclopedia of Optimization", 2008, SPRINGER PUB.</text><article><book><author><name>CHRISTODOULOS A. FLOUDASPANOS M. PARDALOS</name></author><book-title>Encyclopedia of Optimization</book-title><imprint><name>Springer Pub.</name><pubdate>20080000</pubdate></imprint></book></article></nplcit></exch:citation><exch:citation cited-phase="APP" sequence="16"><nplcit num="14" npl-type="s"><text>KORKEGIAN, A. ET AL., SCIENCE, 2005</text><article><author><name>KORKEGIAN, A. et al.</name></author><serial><sertitle>Science</sertitle><pubdate><sdate>20050000</sdate></pubdate></serial></article></nplcit></exch:citation><exch:citation cited-phase="APP" sequence="17"><nplcit num="15" npl-type="s" extracted-xp="029653539"><text>GOLDENZWEIG AGOLDSMITH MHILL SEGERTMAN OLAURINO PASHANI YDYM OUNGER TALBECK SPRILUSKY J: "Automated Structure- and Sequence-Based Design of Proteins for High Bacterial Expression and Stability", MOL CELL, vol. 63, no. 2, 21 July 2016 (2016-07-21), pages 337 - 346, XP029653539, DOI: 10.1016/j.molcel.2016.06.012</text><article><author><name>GOLDENZWEIG AGOLDSMITH MHILL SEGERTMAN OLAURINO PASHANI YDYM OUNGER TALBECK SPRILUSKY J</name></author><atl>Automated Structure- and Sequence-Based Design of Proteins for High Bacterial Expression and Stability</atl><serial><sertitle>Mol Cell</sertitle><pubdate><sdate>20160721</sdate></pubdate><vid>63</vid><ino>2</ino><doi>10.1016/j.molcel.2016.06.012</doi></serial><location><pp><ppf>337</ppf><ppl>346</ppl></pp></location></article></nplcit></exch:citation><exch:citation cited-phase="APP" sequence="18"><nplcit num="16" npl-type="s"><text>AMENGUAL-RIGO PGUALLAR VTAWFIK DSFLEISHMAN SJ: "Automated Design of Efficient and Functionally Diverse Enzyme Repertoires", MOL CELL, vol. 72, no. 1, 4 October 2018 (2018-10-04), pages 178 - 186</text><article><author><name>AMENGUAL-RIGO PGUALLAR VTAWFIK DSFLEISHMAN SJ</name></author><atl>Automated Design of Efficient and Functionally Diverse Enzyme Repertoires</atl><serial><sertitle>Mol Cell</sertitle><pubdate><sdate>20181004</sdate></pubdate><vid>72</vid><ino>1</ino></serial><location><pp><ppf>178</ppf><ppl>186</ppl></pp></location></article></nplcit></exch:citation><exch:citation cited-phase="APP" sequence="19"><nplcit num="17" npl-type="s"><text>WARSZAWSKI, S ET AL.: "Optimizing antibody affinity and stability by the automated design of the variable light-heavy chain interfaces.", PLOS COMPUT. BIOL., vol. 15, 2019, pages e1007207</text><article><author><name>WARSZAWSKI, S et al.</name></author><atl>Optimizing antibody affinity and stability by the automated design of the variable light-heavy chain interfaces.</atl><serial><sertitle>PLoS Comput. Biol.</sertitle><pubdate><sdate>20190000</sdate></pubdate><vid>15</vid></serial><location><pp><ppf>e1007207</ppf></pp></location></article></nplcit></exch:citation></exch:references-cited></exch:bibliographic-data><exch:abstract lang="en" data-format="docdba" abstract-source="national office"><exch:p>Provided herein is a method for obtaining a humanized antibody based on a non-human antibody having an affinity to an antigen of interest, that starts from an experimental or model structure, grafts the non-human CDRs oonn aa library of human frameworks and uses restrained/constrained atomistic simulations to relax and rank the designs by energy.</exch:p></exch:abstract><exch:abstract lang="fr" data-format="docdba" abstract-source="national office"><exch:p>L'invention concerne un procédé permettant d'obtenir un anticorps humanisé à base d'un anticorps non humain ayant une affinité pour un antigène d'intérêt, qui démarre à partir d'une structure expérimentale ou de modèle, greffe des CDR non humains sur une bibliothèque de structures humaines et utilise des simulations atomistiques restreintes/contraintes pour détendre et classer les conceptions par énergie.</exch:p></exch:abstract></exch:exchange-document>